You are here

  • Home
  • Archive
  • Volume 75, Issue 11
  • Disease activity-guided dose optimisation of adalimumab and etanercept is a cost-effective strategy compared with non-tapering tight control rheumatoid arthritis care: analyses of the DRESS study

Citation Tools

Article menu
Download PDFPDF
Clinical and epidemiological research
Extended report
Disease activity-guided dose optimisation of adalimumab and etanercept is a cost-effective strategy compared with non-tapering tight control rheumatoid arthritis care: analyses of the DRESS study

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Kievit W, van Herwaarden N, van den Hoogen FH, et al
Disease activity-guided dose optimisation of adalimumab and etanercept is a cost-effective strategy compared with non-tapering tight control rheumatoid arthritis care: analyses of the DRESS study
Annals of the Rheumatic Diseases 2016;75:1939-1944.